<DOC>
	<DOCNO>NCT01819155</DOCNO>
	<brief_summary>This study provide Senegal Ministry Health data safety immunogenicity adjuvanted trivalent inactivate influenza vaccine ( adjTIV ) full-dose seasonal non-adjuvanted trivalent inactivate influenza vaccine ( TIV ) child . This data inform future policy consideration influenza vaccine . The study power detect significant difference vaccine group , hypothesis test ; therefore , immunogenicity safety objective analyze descriptively .</brief_summary>
	<brief_title>Immunogenicity Safety Trial Adjuvanted Non-adjuvanted Trivalent Influenza Vaccine Tropical Africa</brief_title>
	<detailed_description>The phase 2b , single-center , randomize , observer-blind , parallel group , placebo-controlled trial immunogenicity safety adjTIV seasonal TIV among healthy child age 6 month 71 month town Niakhar , Senegal . A total 300 healthy child randomize 2:2:1 ratio adjTIV TIV placebo . Each child receive two dos one three study vaccine , dose give 28 day apart . Each child follow closely safety dose period one month post-dose two 3 month post-dose two . For determination immune response vaccination background influenza infection , 3 mL blood obtain three time point : pre-vaccination , 28 day post-dose one ( prior receipt dose two ) , 28 day post-dose two . Serum anti-influenza antibody produce virus strain contain vaccine detect use hemagglutination inhibition assay .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female child least 6 month age 6 year age ( yet reach 72 month age ) enrollment visit . Free obvious health problem , establish medical history screening evaluation , include physical examination . Subject 's parent legal guardian willing provide write informed consent prior subject 's first study vaccination . Known hypersensitivity component adjTIV TIV ( include egg protein ) placebo . Receipt nonstudy vaccine within two week prior enrollment refusal postpone receipt vaccine Day 56 visit . Previous receipt influenza vaccine . Hypersensitivity previous administration vaccine . Acute illness accompany body temperature 37.5°C great ( axillary measurement ) within 14 day enrollment visit . ( Enrollment administration adjTIV , TIV , placebo postpone least 14 day recovery . Minor illness , mild upper respiratory infection , axillary temperature &lt; 37.5°C , reason exclusion postpone study vaccination . ) Any condition , opinion investigator , would pose health risk participant he/she participate study would interfere evaluation study objective .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>71 Months</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>influenza</keyword>
	<keyword>influenza vaccine</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>Africa</keyword>
	<keyword>Senegal</keyword>
</DOC>